Endothelin type A receptor (ET A ) is a member of the superfamily of G protein-coupled receptors. Our laboratory conducted a microarray screen that identified ET A as target of HOXA10 transcriptional control in endometrium. Here, we confirm HOXA10-regulated ET A expression in endometrium. Endometrial biopsies were obtained from fertile reproductive-age individuals, and first trimester decidual samples were obtained at the time of elective termination. Immunohistochemistry (IHC) was used to identify ET A protein in endometrium as well as first trimester decidua. ET A was expressed in endometrial stromal cells throughout the menstrual cycle. ET A was also highly expressed in first trimester decidual cells. The regulatory relationship between HOXA10 and ET A was established by transient transfection analysis. The human endometrial stromal cell line (HESC) and the human endometrial epithelial cell line (Ishikawa) were transfected with pcDNA/HOXA10, HOXA10 small interfering RNA (siRNA), or respective controls. Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) was performed to determine expression levels of HOXA10 and ET A in each group. ET A gene expression increased 9-fold (P < .05) after pcDNA/HOXA10 transfection of HESC. ET A was not regulated by HOXA10 in Ishikawa cells. We conclude that ET A is expressed in normal endometrium and decidua. Expression of this receptor is regulated by an essential mediator of endometrial receptivity, HOXA10. ET A may enhance the proliferative potential of endometrial cells in a manner similar to that seen in vascular smooth muscle cells. ET A likely acts as a molecular mechanism by which HOXA10 promotes stromal cell growth and prostaglandin production in both the implantation window and decidua.
INTRODUCTION
The proteins endothelin-1 (ET-1), -2 (ET-2), and -3 (ET-3) comprise a family of 21-amino acid peptides with potent vasoactive properties. 1 In addition, endothelins promote proliferation of vascular smooth muscle and other cells. While originally described as a product of endothelial cells, the endothelins are expressed in multiple epithelial cell types, including endometrial epithelial cells. 2 They function through binding 2 G proteincoupled receptors, endothelin type A receptor (ET A ) and endothelin type B receptor (ET B ). The ET A receptor has a high specificity for ET-1, while ET B binds all 3 endothelins with equipotent affinity. ET A and ET B receptor expression has also been described in the human endometrium. ET A is expressed primarily in the stroma throughout the menstrual cycle while ET B is expressed in the glands in the secretory phase and menstrual stroma. [3] [4] [5] Endothelin-1 is believed to promote both endometrial vasoconstriction at menses through its action on endometrial vasculature and also the subsequent proliferation seen during endometrial regeneration through a direct effect on endometrial stromal cells. 6 The ET A receptor is also expressed in decidua, where it mediates prostaglandin production from first trimester cells. 5 We previously conducted a microarray screen of murine endometrium after transfection with pcDNA/HOXA10 or antisense-HOXA10. 7 We identified ET A as a putative target gene of HOXA10 regulation in the mouse uterus. HOXA10 is a transcription factor that is necessary for endometrial receptivity and embryo implantation. Altering the endometrial expression levels of HOXA10 in murine endometrium results in corresponding alterations in embryo implantation. 8, 9 HOXA10 is also expressed in human endometrium, where its transcription is regulated by estradiol and progesterone. 9,10 Endometrial epithelial HOXA10 expression levels are upregulated in the mid-luteal phase and stromal upregulation is required for normal decidualization. 8, 9 Here, we characterize the expression of ET A in the human endometrium and in the decidua. We also demonstrate the regulation of endometrial ET A expression by HOXA10.
MATERIAL AND METHODS

Tissue Collection
Ten endometrial biopsies (4 proliferative phase and 6 secretory phase) were obtained from fertile women as controls. All women were of reproductive age, had regular menstrual cycles, and had not used hormonal medication within 3 months of surgery. Five first trimester decidual samples were obtained at the time of elective pregnancy termination. Written informed consent was obtained from all participants. Approval was obtained from the Yale University School of Medicine Human Investigations Committee.
Plasmids and Small Interfering RNA
HOXA10 complementary DNA (cDNA) was cloned into the EcoRI site of pcDNA3.1(þ) (Invitrogen, California). pcDNA3.1(þ) without the HOXA10 insert was used as a control (Invitrogen). SiGenome duplex HOXA10 small interfering RNA (siRNA; cat# B-002000-UB-015) and control nontargeting siRNA (cat# D-001210-02) were purchased from Dharmacon, Lafayette, Colorado.
Cell Culture
The human endometrial stromal cell line (HESC), human endometrial adenocarcinoma cell line (Ishikawa), and primary human decidual cells were generous gifts of Charles J. Lockwood, Richard Hochberg, and Susan Richman, respectively (all of Yale University). Cells were maintained in a phenol red-free Dulbecco's Modified Eagle Medium (DMEM), Ham's F-12, and minimal essential medium (MEM), respectively (Sigma, St Louis, Missouri). Each was supplemented with 10% charcoalstripped calf serum, 1% penicillin/ streptomycin, and 1% sodium pyruvate.
Transient Transfection of Human Cell Lines
Human endometrial stromal cell lines, grown to 60% to 70% confluence, were transfected using TransIT-LT1 Mirus (Madison, Wisconsin) with either pcDNA3.1(þ)/ HOXA10 (0.4 mg for 6-well plates, 12 mg for 10-cm dish) or HOXA10 siRNA (20 mmol/L for 6-well plates, 60 mmol/L for 10-cm dish), using empty pcDNA3.1(þ) or nonspecific siRNA as respective controls. Ishikawa cells, grown to 45% to 55% confluence, were transfected using lipofectamine 2000 (Invitrogen) with either pcDNA3.1(þ)/HOXA10 (0.4 mg for 6-well plates, 12 mg for 10-cm dish) or HOXA10 siRNA (20 mmol/L for 6-well plates, 60 mmol/L for 10-cm dish), using empty pcDNA3.1(þ) or nonspecific siRNA as respective controls. Forty-eight hours posttransfection, total RNA was isolated. All transfection experiments were conducted in triplicate.
Real-Time Polymerase Chain Reaction
Real-time quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) was performed using the Lightcycle SYBR Green RT-PCR kit from Roche, Nutley, NJ. One microgram of total RNA was reverse transcribed in 20 mL of reaction mixture containing l0 mmol/L each of deoxyadenosine triphosphate (dATP), deoxycytidinc triphosphate (dCTP), deoxyguanosine triphosphate (dGTP), and deoxythymidine triphosphate (dTTP); 20 pmol oligo (dT); 40 U/mL ribonuclease inhibitor, 10 U/mL avian myeloblastosis virus-reverse transcriptase (AMVRT), and 10Â AMVRT buffer for 30 minutes at 61 C. Polymerase chain reaction amplifying HOXA10 was performed for 45 cycles at 95 C for 2 seconds, 65 C for 5 seconds, and 72 C for 18 seconds. Polymerase chain reaction amplifying b-actin as a control was performed for 45 cycles at 95 C for 2 seconds, 61 C for 5 seconds, and 72 C for 18 seconds. Polymerase chain reaction amplifying ET A was performed for 45 cycles at 95 C for 2 seconds, 65 C for 5 seconds, and 72 C for 18 seconds. The HOXA10 and ET A intron spanning primers were selected using the primer selection program Primer3 developed by the Whitehead Institute for Biomedical Research. The primers selected yield a 211 bp reaction product from messenger RNA (mRNA) and a 1389 bp DNA reaction product from DNA, which allowed control for possible DNA contamination.
HOXA10
:
The Roche Light Cycler monitored the increasing fluorescence of PCR products during amplification. A quantitative standard curve was then created. Quantification of samples was determined with the Roche Light Cycler and adjusted to the quantitative expression of b-actin from these same samples. Melting curve analysis was conducted to determine the specificity of the amplified products and to ensure the absence of primer-dimer formation. All products obtained yielded the predicted melting temperature. Three independent experiments were conducted at each concentration.
Immunohistochemistry ET A was evaluated by immunohistochemistry (IHC) using a rabbit polyclonal antibody to ET A (Abcam, Inc., Cambridge, MA). The specimens were embedded in paraffin and serial 5-mm sections obtained. The sections were deparaffinized in xylene and ethanol. Endogenous peroxidase was blocked with 3% H 2 O 2 . After a 45-minute incubation with 1.5% normal goat blocking serum, the sections were incubated overnight at 4 C with primary antibody (anti-ET A 1:300). The sections were then incubated with biotinylated goat anti-rabbit secondary antisera for 60 minutes, avidin and biotinylated peroxidase (Vectastain; Vector Laboratories, Burlingame, California) for 45 minutes, and diaminobenzidine (400 mg/mL) for 45 seconds. Hematoxylin and Li 2 CO 3 were used for counterstaining. One hundred consecutive cells in 5 nonadjacent microscopic fields were evaluated for staining to quantify the expression of each cell-type specific marker.
Statistics
Quantitative PCR results were compared using the t test.
RESULTS
ET A Is Expressed in Human Endometrium and Decidua
In normal human endometrium, IHC results demonstrate that ET A was expressed in endometrial stromal cells throughout the menstrual cycle ( Figure 1A-C) . ET A was expressed at high levels within the cytoplasm of subset of stromal cells. No significant variation was observed in ET A expression throughout the menstrual cycle in either glands or stroma.
ET A Expression Persisted in the Decidua of Pregnancy
The first trimester decidua demonstrated high levels of ET A expression ( Figure 1D ). ET A was also more highly expressed in first trimester decidua compared to proliferative or secretory phase endometrium.
ET A Expression Is Regulated by HOXA10
To determine whether ET A was regulated by HOXA10, we performed transient transfection with a HOXA10 expression construct or HOXA10 siRNA. Successful transfection and increased/decreased HOXA10 expression was confirmed using the real-time PCR (Figure 2 ). Real-time PCR demonstrated that pcDNA3.1/ HOXA10 transfection increased ET A mRNA expression 9-fold compared to that obtained using empty pcDNA as a control in HESC (P < .05). ET A mRNA expression was decreased 50-fold after HOXA10 siRNA transfection compared to control siRNA transfection in HESC (P < .05). Transfection with either pcDNA3.1/HOXA10 or HOXA10 siRNA did not alter ET A expression in Ishikawa cells, suggesting that ET A was not regulated by HOXA10 in glandular epithelium.
DISCUSSION
The endothelins are a family of proteins with vasoactive properties. Endothelin-1 was originally isolated from porcine aortic endothelial cells; subsequently, 2 other isoforms, ET-2 and ET-3, have been described. 11, 12 Endothelins are also produced from nonendothelial cell types, including cardiac myocytes, cells of the adrenal zona glomerulosa, follicular cells, and Sertoli cells. The endothelins in general, and in particular ET-1, also appear to play a role in mitogenesis of smooth muscle cells and fibroblasts. 6 These actions are mediated by the binding of endothelins to 2 pharmacologically distinct G protein-coupled receptors, ET A and ET B . The ET A receptor has high specificity for ET-1 (about 100 times that of ET-2 and -3 isoforms), while the ET B receptor binds all 3 endothelins with equal affinity. 13 Endothelin-1 has also emerged in recent years as an essential modulator of reproductive function, where it is involved in contraction of seminiferous tubes, inhibition of follicular cells, propagation of the luteolytic process, and endometrial receptivity. [14] [15] [16] The action of ET-1 in the corpus luteum is linked to progesterone-induced ET A expression; ET A mRNA levels are upregulated in the luteal phase, allowing ET-1 to bind to ET A receptors present on corpus luteal cells. 17 ET A subsequently regulates blood flow via its expression on smooth muscle cells, where ET-1 binding elicits an increase in intracellular Ca 2þ and inositol and subsequent vasoconstriction. 18, 19 In the human uterus, ET-1 is expressed in vascular endothelium, stroma as well as glandular and luminal epithelium. [20] [21] [22] [23] The mRNA for both ET A and ET B receptor subtypes are expressed as well. 6 Our results, demonstrating the presence of ET A in human endometrium, corroborate these data. The ET A receptor may regulate a number of endometrial functions including menstruation, mitogenesis, and the release of other paracrine agents. 6, 24 Here, we have shown that HOXA10 regulates ET A receptor expression in endometrium. In addition, HOXA10 expression is greatest in decidua, a tissue that expresses more ET A than proliferative or secretory phase endometrium, suggesting a regulatory role for HOXA10 in decidual ET A receptor expression in vivo.
While stromal/decidual expression of ET A is regulated by HOXA10, expression in epithelial cells is not highly regulated, likely due to the limited role that these cells play in early pregnancy. Stromal/decidual cells normally proliferate in early pregnancy; HOXA10-deficient mice demonstrate diminished stromal and decidual cell proliferation. HOXA10 action may be mediated, at least in part, through its regulation of ET A in the decidua and the known effects of ET A on cell proliferation.
HOX genes are transcription factors that regulate a vast number of downstream target genes; in particular, HOXA10 regulates endometrial gene expression necessary for embryo implantation and viability. 7, [25] [26] [27] [28] In the uterus, specific targets of HOXA10 include genes that are important for decidualization such as insulin-like growth factor binding protein 1 (IGFBP-1), EMX2, prolactin, and the Prostaglandin E receptor subtype EP2 and subtype EP4. [29] [30] [31] [32] [33] [34] Here, we demonstrate that HOXA10 also regulates ET A , likely promoting endometrial receptivity and decidualization; ET A activation specifically promotes proliferation as well as vascular adaptation of the endometrium to decidualization and pregnancy.
Activation of ET A is known to induce prostaglandin production in decidua. 35, 36 HOXA10 directly induces expression of prostaglandin receptors as well as prostaglandin production through ET A . This leads to the establishment of a system that has the coordinated ability to both produce and respond to prostaglandins. ET A receptor is in a position to stimulate prostaglandin production and simultaneously prostaglandin receptors are also expressed. Thus, the HOXA10-mediated developmental pathway establishes all of the conditions needed to respond to prostaglandins, however, limits this response to a biologically appropriate one that requires input from ET-1.
In conclusion, we report for the first time the regulation of expression of ET A by HOXA10 in endometrial cells. We also show the expression of this protein during the menstrual cycle and in first trimester decidua. ET A likely functions via a molecular mechanism by which HOXA10 promotes stromal cell activation in a manner similar to that seen in vascular smooth muscle cells. 
